Results of Open-Label Non-Randomized Comparative Clinical Trial: Bromhexine and Spironolactone for Coronavirus Infection Requiring Hospitalization (BISCUIT)

The study assessed the efficacy and safety of bromhexine and spironolactone in treating mild to moderate COVID-19 in 103 patients. The combination treatment led to a statistically significant reduction in hospitalization time from 10.4 to 9.0 days and fever duration from 6.5 to 3.9 days. In matched patients, temperature normalized 2 days faster in the treatment group compared to controls. By the 10th day, virus elimination was achieved in all patients in the treatment group, while 23.3% of the control group still had viremia. The odds of having a positive PCR or extended hospitalization were significantly lower in the treatment group. No side effects were reported, suggesting the combination was effective in improving clinical outcomes and reducing viral load or hospitalization duration.